Efficacy and safety of Venetoclax-based regimens in relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials
| Autor: | Wei He, Fang He, Huixian Hu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Annals of Medicine, Vol 55, Iss 1, Pp 1029-1036 (2023) |
| Druh dokumentu: | article |
| ISSN: | 07853890 1365-2060 0785-3890 |
| DOI: | 10.1080/07853890.2023.2186480 |
| Popis: | AbstractBackground Multiple myeloma (MM) is an incurable malignancy. Venetoclax (VEN) shows a meaningful effect in MM patients who are relapsed or refractory (RR) to previous standard therapies.Objective This study aimed to assess the efficacy and safety of VEN-based treatments in RR MM patients.Materials and methods Comprehensive studies were searched in PubMed, Embase, Web of Science and Cochrane library. Efficacy was assessed by overall response rate (ORR), strict complete response rate (sCR), complete response rate (CR), very good partial response rate (VGPR) and partial response rate (PR).Results Seven studies containing 482 subjests were included. The pooled ORR, ≥ CR (sCR + CR), VGPR and PR were 68% (51%–85%), 24% (13%–35%), 25% (17%–34%) and 17% (11%–24%) respectively. Multi-drug treatments were superior to VEN ± dexamethasone (Dex) treatments in ORR (82% vs 42%, p = .003) and ≥ CR (36% vs 7%, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|